Brind.

Agenus, led by CEO Garo H. Armen, is a significant stakeholder in MiNK Therapeutics.

4 reports, 3 independent Updated Aug 26
Gone quiet Reached 3 outlets in its first 24 hours
Reports
4
Developments
3
Repetition
25%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 3 independent outlets

Agenus, led by CEO Garo H. Armen, is a significant stakeholder in MiNK Therapeutics.

Who's involved

What this event is mainly about
AgenusMiNK Therapeutics (United States)

How it developed

Newest first. Tap a step to see who reported it.
  1. Agenus, led by Garo H. Armen, holds a significant stake in MiNK Therapeutics.1 source
  2. DOD granted MiNK Therapeutics funding for iNKT research into GvHD.1 source
  3. Agenus holds 55% of MiNK Therapeutics shares, and Yekaterina Chudnovsky is also a shareholder.1 source

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • Business WireUpdate: Agenus Aug 27 Stakeholder Webcast—Transformative IO Updates, BOT/BAL Data, BATTMAN Preview, Zydus Partnership Momentum, and MiNK Spotlight Webcast details updated from the August 11th release
  • Business WireAgenus to Unveil BOT/BAL Strategic Advancements, Key Milestones, and Future Outlook in Virtual Stakeholder Briefing on August 27, 2025 LEXINGTON, Mass., August 19, 2025--(BUSINESS WIRE)--Agenus Inc.
  • GlobeNewswireMiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric Cancer Department of
  • Simply Wall St.MiNK Therapeutics, Inc.'s (NASDAQ:INKT) biggest owners are public companies who got richer after stock soared 815% last week The considerable ownership by public companies in MiNK Therapeutics indica